石藥(01093)治療乳腺癌注射液內地上市申請獲受理

　　石藥(01093)宣布，附屬石藥集團巨石生物製藥有限公司開發的帕妥珠單抗注射液，其上市申請已獲中國藥監局受理，其適應症為HER2陽性乳腺癌。
《經濟通通訊社12日專訊》

【你點睇？】本港多間航企4月起再次調高燃油附加費，你認為政府應否介入審批航空燃油附加費？你會否因費用增加而減少乘搭飛機出行？► 立即投票

備註：	即時報價更新時間為31/03/2026 07:48
	港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。